Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Deferred Tax Liability (2017 - 2025)

Historic Non-Current Deferred Tax Liability for Ascendis Pharma A (ASND) over the last 3 years, with Q3 2025 value amounting to $12.0 million.

  • Ascendis Pharma A's Non-Current Deferred Tax Liability rose 2555.14% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 2555.14%. This contributed to the annual value of $7.9 million for FY2024, which is 2523.43% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Non-Current Deferred Tax Liability stood at $12.0 million, which was up 2555.14% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Non-Current Deferred Tax Liability registered a high of $12.0 million during Q3 2025, and its lowest value of $6.3 million during Q4 2023.
  • For the 3-year period, Ascendis Pharma A's Non-Current Deferred Tax Liability averaged around $8.8 million, with its median value being $8.2 million (2024).
  • Examining YoY changes over the last 5 years, Ascendis Pharma A's Non-Current Deferred Tax Liability showed a top increase of 3195.63% in 2025 and a maximum decrease of 568.22% in 2025.
  • Over the past 3 years, Ascendis Pharma A's Non-Current Deferred Tax Liability (Quarter) stood at $6.3 million in 2023, then increased by 23.64% to $7.8 million in 2024, then surged by 54.95% to $12.0 million in 2025.
  • Its last three reported values are $12.0 million in Q3 2025, $10.9 million for Q2 2025, and $8.1 million during Q1 2025.